The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Use of the GUARDANT360 noninvasive tumor sequencing assay on 300 patients across colorectal, melanoma, lung, breast, and prostate cancers and its clinical utility.
AmirAli Talasaz
Employment or Leadership Position - Guardant Health
Stock Ownership - Guardant Health
Other Remuneration - Guardant Health
Stefanie Mortimer
Employment or Leadership Position - Guardant Health
Stock Ownership - Guardant Health
Other Remuneration - Guardant Health
Dragan Sebisanovic
Employment or Leadership Position - Guardant Health
Stock Ownership - Guardant Health
Other Remuneration - Guardant Health
LaiMun Siew
Employment or Leadership Position - Guardant Health
Stock Ownership - Guardant Health
Other Remuneration - Guardant Health
Aubrey Zapanta
Employment or Leadership Position - Guardant Health
Other Remuneration - Guardant Health
Gangwu Mei
Employment or Leadership Position - Guardant Health
Stock Ownership - Guardant Health
Other Remuneration - Guardant Health
Ben Schiller
Employment or Leadership Position - Guardant Health
Stock Ownership - Guardant Health
Other Remuneration - Guardant Health
Helmy Eltoukhy
Employment or Leadership Position - Guardant Health
Stock Ownership - Guardant Health
Other Remuneration - Guardant Health